Business Context and Reporting Period
Protagonist Therapeutics, Inc. filed its Form 10-K for the fiscal year ended December 31, 2016, including unaudited fourth-quarter information. The company is a clinical-stage biopharmaceutical developer focused on constrained peptide therapeutics, particularly oral, GI-restricted candidates for inflammatory bowel disease.
- PTG-100: Completed a Phase 1 trial in June 2016 and initiated a global Phase 2b ulcerative colitis trial in the fourth quarter of 2016.
- PTG-200: In IND-enabling studies for Crohn’s disease; Phase 1 initiation was planned for 2017.
- PTG-300: Preclinical hepcidin mimetic for iron-overload disorders; IND-enabling work was expected to be completed in the first half of 2017.
- The company had no approved products and had generated no product-sales revenue.
Financial Performance and Liquidity
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Product revenue | None | None | No product revenue in either period |
| Research and development expense | $25.7 million | $11.8 million | Up 117% |
| General and administrative expense | $7.0 million | $3.0 million | Up 135% |
| Total operating expenses | $32.7 million | $14.8 million | Up 121% |
| Net loss | $37.2 million | $14.9 million | Loss increased $22.3 million |
| Net loss attributable to common stockholders | $37.7 million | $14.9 million | Loss increased $22.8 million |
| Basic and diluted loss per share | $5.80 loss | $59.32 loss | Improved because of the IPO and share-count increase |
| Cash used in operating activities | $30.0 million | $14.4 million | Use increased $15.6 million |
Operating margins and profitability metrics are not meaningful because the company had no product revenue and reported continuing operating losses. Research and development represented approximately 79% of total operating expenses and increased primarily because of PTG-100 clinical development, contract manufacturing, consultants, preclinical activities, and headcount.
- Cash, cash equivalents and available-for-sale securities totaled $87.7 million at December 31, 2016, compared with $11.9 million at December 31, 2015.
- Cash and cash equivalents were $21.1 million; available-for-sale securities were $66.7 million, including $10.2 million classified as noncurrent.
- Working capital was $76.8 million and total stockholders’ equity was $87.6 million.
- The company had no outstanding debt at year-end and no credit facility or committed financing source.
- Cash provided by financing activities was $106.3 million, including $83.6 million of net IPO proceeds and $22.5 million from preferred-stock financing.
- Cash used in investing activities was $59.3 million, primarily reflecting purchases of available-for-sale securities.
- Management believed existing liquidity would fund operations and capital expenditures for at least the next 12 months, but stated that substantial additional capital would be required to complete clinical development and potentially commercialize products.
Material Changes Versus the Prior Comparable Period
- R&D spending more than doubled as PTG-100 advanced through Phase 1 and into Phase 2b, while PTG-200 and PTG-300 progressed through preclinical and IND-enabling work.
- G&A expense more than doubled because of increased personnel, professional fees and public-company costs.
- The company recorded a $4.7 million charge from changes in the fair value of redeemable convertible preferred-stock tranche and warrant liabilities, compared with a $0.1 million charge in 2015. These liabilities were eliminated or converted in connection with preferred-stock transactions and the IPO.
- In August 2016, the company completed its IPO, issued 7.5 million shares at $12.00 per share, and received $83.6 million in net proceeds. An additional 252,972 shares were issued in September 2016 under the underwriters’ option.
- All outstanding redeemable convertible preferred stock converted into 8.6 million common shares at the IPO; no preferred stock remained outstanding at year-end.
- Shares outstanding increased to 16.7 million at December 31, 2016 from 272,409 at December 31, 2015, reflecting the IPO, preferred-stock conversion and reverse stock split.
- Stock-based compensation increased to $2.1 million from $99,000, with $12.6 million of unrecognized compensation cost remaining at year-end.
Guidance, Outlook, Risks and Unusual Items
- Management expected to complete the PTG-100 Phase 2b study and report top-line data in the second half of 2018, subject to enrollment, trial execution and regulatory requirements.
- An interim futility analysis for PTG-100 was expected in the second half of 2017.
- Management planned to initiate Phase 1 trials for PTG-200 and PTG-300 in 2017, with PTG-300 Phase 1 data expected by year-end 2017.
- The company expected continued losses and negative cash flows for the foreseeable future and acknowledged that its existing resources would not fund pivotal clinical trials.
- PTG-300 obligations include a $250,000 payment upon initiation of a Phase 1 trial and potential aggregate development, regulatory and sales milestones of up to $128.5 million, plus low-single-digit royalties on worldwide net sales.
- In March 2017, the company entered into a seven-year lease for a larger Newark, California facility, with aggregate minimum payments of approximately $13.4 million and a $450,000 security deposit.
- Key risks include clinical-trial failure or delay, regulatory nonapproval, patient-enrollment challenges, adverse safety findings, competition from established biologics and pipeline therapies, dependence on contract research organizations and manufacturers, intellectual-property challenges, reimbursement uncertainty and the need for additional financing.
- The company disclosed continuing material weaknesses in internal control over financial reporting related to complex equity transactions and review of manual journal entries. Disclosure controls and procedures were deemed ineffective as of December 31, 2016, although remediation efforts were underway.
- The company had no material pending legal proceedings and no off-balance-sheet arrangements.
Most Important Facts for Investors to Verify
- Whether PTG-100 Phase 2b enrollment, interim analysis and data timelines remain achievable and whether efficacy is demonstrated in ulcerative colitis.
- The company’s cash-burn rate, investment maturities and projected liquidity runway relative to the cost of Phase 2b, Phase 3 and other development programs.
- The timing and terms of any future equity, debt, licensing or collaboration financing, including potential shareholder dilution.
- Progress toward remediation of the disclosed material weaknesses and the effectiveness of the new accounting systems and controls.
- Whether PTG-200 and PTG-300 meet their stated IND-enabling and Phase 1 milestones.
- The scope and enforceability of patents covering PTG-100, PTG-200, PTG-300 and the underlying peptide platform.
- Potential milestone and royalty obligations to Zealand Pharma and any future rights exercised by Johnson & Johnson Development Corporation.